Skip to content

EV / EBITDA at other companies

GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
13.3×-0.8×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
1,820.6×
Revvity logo
RevvityRVTY
16.7×-2.2×
Labcorp Holdings logo
Labcorp HoldingsLH
13.3×-1.4×
Agilent Technologies logo
Agilent TechnologiesA
18.8×-0.5×
Danaher logo
DanaherDHR
20.5×-2.1×

Other financials

Income statement

See full
Revenue$377.3M+1.2%
Gross profit$230.9M-2.9%
Operating income$81.3M-20.3%
Net income$118.4M+62.3%
EPS (diluted)$1.80+76.5%

Balance sheet

See full
Cash & equivalents$500.3M-46.8%
Total debt$627.9M+1.8%
Total equity$1.2B+4.1%
Total assets$2.3B+14.2%

Cash flow

See full
Operating cash flow$125.1M+16.3%
CapEx$3.2M-63.0%
Free cash flow$121.9M+23.3%

Valuation

See full
Market cap$6.76B-26.3%
Enterprise value$6.89B-20.5%
P/E24.2×-10.2×
P/S4.4×-1.6×

Profitability

See full
Gross margin60.5%-3.6pp
Operating margin18.8%-10.7pp
Net margin18%+0.7pp
FCF margin24.4%-6.4pp

Returns & leverage

See full
Return on equity23.5%-1.7pp
Debt / equity0.5×0.0×
Current ratio2.8×-2.9×

Where this comes from

Calculated from Lantheus Holdings’s reported figures.

Based on the most recent quarter.

The official record: Lantheus Holdings’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lantheus Holdings's EV / EBITDA?
Lantheus Holdings (LNTH) reported EV / EBITDA of 13.7× in Q1 2026.
How has Lantheus Holdings's EV / EBITDA changed year-over-year?
Lantheus Holdings's EV / EBITDA increased by 10.9% year-over-year, from 12.4× to 13.7×.
What is the long-term trend for Lantheus Holdings's EV / EBITDA?
Over 3 years (2020 to 2025), Lantheus Holdings's EV / EBITDA has grown at a -38.2% compound annual growth rate (CAGR), from 52.1× to 12.3×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.